Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth.

Xun MaSandy W WongPing ZhouChakra P ChaulagainParul DoshiAndreas K KleinKellie SpragueAdin KugelmassDenis ToskicMelissa WarnerKenneth B MillerLisa LeeCindy VargaRaymond L Comenzo

Published in: Experimental hematology & oncology (2018)

In vitro, daratumumab is not toxic to mobilized CD34+ progenitor cells from myeloma patients.

Keyphrases

newly diagnosed
end stage renal disease
multiple myeloma
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
peripheral blood
patient reported outcomes
oxidative stress